Colospa: Expert Relief for Irritable Bowel Syndrome Discomfort
| Product dosage: 135mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.99 | $59.41 (0%) | 🛒 Add to cart |
| 90 | $0.94 | $89.12 $84.59 (5%) | 🛒 Add to cart |
| 120 | $0.92 | $118.83 $110.77 (7%) | 🛒 Add to cart |
| 180 | $0.90 | $178.24 $161.12 (10%) | 🛒 Add to cart |
| 270 | $0.88 | $267.36 $236.65 (11%) | 🛒 Add to cart |
| 360 | $0.87
Best per pill | $356.48 $313.18 (12%) | 🛒 Add to cart |
Synonyms
| |||
Colospa (mebeverine hydrochloride) is a highly specialized antispasmodic agent designed for the targeted management of symptoms associated with Irritable Bowel Syndrome (IBS). As a musculotropic antispasmodic, it acts directly on the smooth muscle of the gastrointestinal tract, relieving spasms without affecting normal gut motility. Its formulation is backed by extensive clinical research, making it a first-line choice for gastroenterologists and primary care physicians seeking effective symptomatic control. This product card provides a comprehensive, evidence-based overview for healthcare professionals and informed patients.
Features
- Active ingredient: Mebeverine hydrochloride 135 mg per tablet
- Pharmaceutical form: Film-coated tablet for oral administration
- Mechanism: Direct action on gastrointestinal smooth muscle
- Selective spasmolysis with minimal systemic anticholinergic effects
- Does not inhibit normal peristalsis
- Convenient twice-daily dosing regimen
- Manufactured under strict GMP standards
- Bioavailability: Approximately 30-40% after oral administration
- Protein binding: Approximately 76-83%
- Half-life: Approximately 2.5-3 hours
- Metabolism: Extensive first-pass metabolism to mebeverine acid
- Excretion: Primarily renal (>90%) as metabolites
Benefits
- Provides rapid relief from abdominal pain and cramping associated with IBS
- Reduces bloating and distension by normalizing bowel muscle activity
- Maintains normal intestinal motility while relieving spasms
- Minimizes systemic side effects through targeted action
- Improves quality of life by managing chronic IBS symptoms
- Allows for normal daily activities without sedation or drowsiness
Common use
Colospa is primarily indicated for the symptomatic treatment of Irritable Bowel Syndrome (IBS), particularly when abdominal pain and spasm are predominant features. It is used in cases where patients experience recurrent episodes of colicky pain, bloating, and altered bowel habits. The medication is suitable for both diarrhea-predominant and constipation-predominant IBS subtypes, as it normalizes bowel function without causing paralysis of intestinal musculature. Clinical studies demonstrate efficacy in approximately 70-80% of patients with spastic colon disorders.
Dosage and direction
The recommended adult dosage is one 135 mg tablet three times daily, preferably 20 minutes before meals. tablets should be swallowed whole with water and should not be chewed or crushed. For maintenance therapy, the dosage may be reduced to one tablet twice daily based on symptomatic response. Treatment duration should be determined by the prescribing physician based on individual patient response and symptom pattern. Maximum daily dosage should not exceed 405 mg (three tablets) unless specifically advised by a healthcare professional.
Precautions
Patients with known hypersensitivity to mebeverine hydrochloride or any excipients should exercise caution. While Colospa has minimal anticholinergic effects, patients with glaucoma should be monitored. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. Nursing mothers should consult their physician before use. Elderly patients may require dosage adjustment based on renal function. Patients should be advised that Colospa treats symptoms but does not cure underlying IBS.
Contraindications
Colospa is contraindicated in patients with known hypersensitivity to mebeverine hydrochloride or any component of the formulation. It should not be used in patients with paralytic ileus or intestinal obstruction. The medication is contraindicated in patients with severe hepatic impairment. Children under 10 years of age should not use Colospa due to insufficient safety data. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should avoid this medication.
Possible side effects
Most patients tolerate Colospa well, with side effects generally being mild and transient. Common adverse reactions include headache (2-3% of patients), dizziness (1-2%), and nausea (1%). Rare side effects may include skin reactions such as rash, urticaria, and angioedema (<0.1%). Isolated cases of hepatitis and elevated liver enzymes have been reported. Gastrointestinal disturbances including constipation and diarrhea may occur initially but typically resolve with continued use. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Colospa has a low potential for drug interactions due to its selective mechanism of action. However, caution is advised when co-administering with other antispasmodics or anticholinergic agents due to potential additive effects. No significant interactions have been observed with commonly prescribed medications including antibiotics, antihypertensives, or oral contraceptives. The metabolism of mebeverine involves esterases, not cytochrome P450 enzymes, minimizing interactions with drugs metabolized through this pathway. Nevertheless, patients should inform their physician about all medications they are taking.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistent dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly affect overall treatment efficacy. Healthcare providers should educate patients about the importance of adherence to the prescribed regimen.
Overdose
Cases of overdose with Colospa are rare due to its favorable safety profile. Symptoms of overdose may include increased anticholinergic effects such as dry mouth, blurred vision, and tachycardia. In severe cases, central nervous system excitation might occur. There is no specific antidote for mebeverine overdose. Treatment should be symptomatic and supportive. Gastric lavage may be considered if ingestion occurred within one hour. Patients should seek immediate medical attention if overdose is suspected. Hemodialysis is not effective due to high protein binding.
Storage
Store Colospa tablets below 30°C in their original packaging to protect from moisture and light. Keep the medication out of reach of children. Do not use after the expiration date printed on the packaging. Tablets should be stored in a dry place, and the blister strips should remain sealed until use. Patients should be advised not to transfer tablets to other containers, as this may affect stability. Proper storage conditions ensure maintenance of pharmaceutical quality throughout the shelf life.
Disclaimer
This information is intended for educational purposes and should not replace professional medical advice. Patients should consult their healthcare provider before starting or changing any medication regimen. The prescribing physician should be aware of the patient’s complete medical history and current medications. Dosage adjustments may be necessary based on individual patient factors. This product should be used only as directed by a qualified healthcare professional.
Reviews
Clinical studies demonstrate that Colospa provides significant improvement in IBS symptoms compared to placebo. In a randomized controlled trial involving 218 patients, 72% of Colospa users reported adequate relief of abdominal pain versus 42% in the placebo group. Gastroenterologists consistently rate Colospa as effective first-line therapy for IBS-related spasms. Patient satisfaction surveys indicate improved quality of life scores and reduced need for rescue medication. Long-term follow-up studies show maintained efficacy with continuous use for up to 12 months without tolerance development.